miR-1290 is a potential prognostic biomarker in non-small cell lung cancer

Journal of Thoracic Disease

Volumn 7, Issue 9, 2015, Pages 1570-1579

  Mo, Dongping ^a   Gu, Bing ^a,b   Gong, Xue ^a   Wu, Lei ^a   Wang, Hong ^a,b   Jiang, Ye ^a,b   Zhang, Bingfeng ^a,b   Zhang, Meijuan ^a,b   Zhang, Yan ^a,b   Xu, Jian ^a,b   Pan, Shiyang ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b National Key Clinical Department of Laboratory Medicine   (China)

Author keywords

Biomarker; MiR 1290; Non small cell lung cancer (NSCLC); Prognosis

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 1290; UNCLASSIFIED DRUG;

ADULT; ALDH4A1 GENE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

EID: 84947437186     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.09.38     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol 2011;6:49-69.
3. Juergens R, Brahmer J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep 2007;9:255-64.
4. Waldman SA, Terzic A. Translating microRNA discovery into clinical biomarkers in cancer. JAMA 2007;297:1923-5.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6):857-66.
6. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
7. Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011;6:e25787.
8. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. Ann Surg 2010;251:499-505.
9. Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77:1265.e9-16.
10. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
11. Jakopovic M, Thomas A, Balasubramaniam S, et al. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol 2013;3:261.
12. Cortinovis D, Monica V, Pietrantonio F, et al. MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. Curr Pharm Des 2014;20:3982-90.
13. Morin RD, O'Connor MD, Griffith M, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008;18:610-21.
14. Yelamanchili SV, Morsey B, Harrison EB, et al. The evolutionary young miR-1290 favors mitotic exit and differentiation of human neural progenitors through altering the cell cycle proteins. Cell Death Dis 2014;5:e982.
15. Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013;19:3600-10.
16. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
17. Liu H, Du L, Wen Z, et al. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis 2013;28:697-703.
18. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10:1470-6.
19. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
20. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
21. Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574-5p Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. J Thorac Oncol 2011;6:482-8.
22. Jia Y, Zang A, Shang Y, et al. MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to nonsmall cell lung cancer in the Chinese population. Med Oncol 2014;31:194.
23. Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008;283:33394-405.
24. Roth C, Kasimir-Bauer S, Pantel K, et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011;5:281-91.
25. Belian E, Kurucz R, Treue D, et al. Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. Anticancer Res 2010;30:629-33.
26. Wu J, Ji X, Zhu L, et al. Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells. Cancer Lett 2013;329:155-63.
27. Pang S, Lynn DA, Lo JY, et al. SKN-1 and Nrf2 couples proline catabolism with lipid metabolism during nutrient deprivation. Nat Commun 2014;5:5048.
28. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008;3:e3694.
29. Taylor MA, Sossey-Alaoui K, Thompson CL, et al. TGFbeta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 2013;123:150-63.
30. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-52.
31. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012;51:473-9.
32. Hötte GJ, Linam-Lennon N, Reynolds JV, et al. Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance. Radiation Res 2012;177:272-9.
33. Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) 2011;121:437-47.
34. Kuriyama S, Yoshida M, Yano S, et al. LPP inhibits collective cell migration during lung cancer dissemination. Oncogene 2015. [Epub ahead of print].
35. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
36. Jones RB, Gordus A, Krall JA, et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006;439:168-74.
37. Kobayashi D, Nomoto S, Kodera Y, et al. Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis. World J Surg 2012;36:362-72.